our work
Publications
Selected publications, reports and talks
Economic Evaluations
Desai K, Torres Rueda S, Mvundura M, Stone J, Kilbourne-Brook M, Indravudh P, Vickerman P. The potential cost-effectiveness and potential health benefits of introducing a multipurpose HIV and pregnancy prevention microarray patch in South Africa. JAIDS. 2025 Feb (under review BMC Public Health).
Desai K, Druyts E, Yan K, Ballijepalli C. On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19? Pharmacoeconomics. 2020 Nov;38(11):1149-1151.
Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J. Cost-effectiveness Analysis of AbobotulinumtoxinA for the Treatment of Cervical Dystonia in the United Kingdom. Clinicoecon Outcomes Res. 2017 Apr 15;9:211-229.
Abogunrin S, Brand S, Desai K, Dinet J, Gabriel S, Harrower T. AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis. ClinicoEconomics and Outcomes Research. 2015 September Volume 7:441-449.
Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, García Alonso F, Fuster V, Sanz G. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015 May 9;5(5).
Möller J, Desai K, Simpson K, Baran RW, Van de Steen O, Dietz B, Gooch K. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? ClinicoEconomics and Outcomes Research. 2020;12:445-457.
Marsh K, Xu P, Orfanos P, Benedict A, Desai K, Griebsch I. Model-based cost-effectiveness analyzes for chronic myeloid leukaemia: challenges. Pharmacoeconomics. 2014 Sep;32(9):853-64.
Grassly NC, Desai K, Pegurri E, Sikazawe A, Malambo I, Siamatowe C, Bundy DAP. The economic impact of HIV/AIDS on the education sector in Zambia. AIDS; 2003, 17(7):1039-44.
Epidemiology
Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020 Mar;12:295-305.
Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Mult Scler Relat Disord. 2020 Jun 4;44:102260.
Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infectious Disease. 2016 Jun 18;16:303.
Amelio J, Cid Ruzafa J, Desai K, Tzivelekis S, Muston D, Khalid JM, Ashman P, Maguire A. Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom. BMC Cancer. 2014 May 24;14:364.
Cid RJ, Cox A, Merinopoulou E, Baggaley R, Leighton P, Desai K. An Epidemiologic Modeling Application To Pharmacoeconomics for Improved Health Care Planning. Value Health. 2014.
Desai K, Jukes M. The impact of AIDS on education and education on AIDS in sub-Saharan Africa. Education for all: literacy for life; EFA global monitoring report, 2006. UNESCO.
Garnett GP, Desai K, Williams J. The Epidemiological Impact of an HIV/AIDS Vaccine in Developing Countries. World Bank Policy Research Working Paper 2811, 2002.
Postma MJ, Desai K, Hollingsworth D, Chapman R. Modeling of Infectious Diseases for Prevention and Mitigation: How Modeling Has Informed Public Health Policy. ISPOR 2012.
Data Analytics and Statistical Methods
López EL, Contrini MM, Mistchenko A, Armoni J, Kieffer A, Baggaley R, DiTanna G, Desai K, Rasuli A. Modeling the long-term persistence of hepatitis A antibody after a two dose vaccination schedule in Argentinean children. Pediatr Infect Dis J. 2015 Apr;34(4):417-25.
Chen X, Bailleux F, Desai K, Qin L, Dunning AJ. A threshold method for immunological correlates of protection. BMC Med Res Methodol. 2013 Mar 1;13:29.
Desai K, Coudeville L, Bailleux F. Modeling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012 Mar 28;30(15):2510-5.
Desai K, Masse BR, Allard P, Latraverse M. Hazard Regression and Recursive Partitioning in Survival Analysis. ASA Proc Biometr Sect 1996, 256-261.
Clinical Trial Simulation and Trial Design
Masse BR, Boily MC, Dimitrov D, Desai K. Efficacy Dilution in Randomized Placebo-Controlled Vaginal Microbicide Trials. Emerging Themes in Epidemiology 2009, 6:5.
Desai K, Boily MC, Masse B, Anderson RM. What is the relative importance of STIs when effectiveness against HIV infection is detected in randomised trials of male circumcision? Emerging Themes in Epidemiology; 2006 3(19).
Desai K, Boily MC, Masse B, Anderson RM. Using Transmission Dynamics Models to Validate Vaccine Efficacy Measures Prior to Conducting HIV Vaccine Efficacy Trials. Chapter in Discrete Epidemiology. AMS, 2006.
Desai K, Boily M-C, Masse BR, Alary M, Anderson RM. Simulation studies of Phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine. Epidemiology and Infection, 1999, 123;65-88.
Desai K, Boily MC, Garnett GP, Masse BR. Statistical power and efficacy estimation in microbicide trials. ISSTDR 2004.
OUR SERVICES
Health economics, epidemiology and data science.
The same rigor behind this research shapes every economic model, epidemiological analysis, and statistical solution we deliver.